Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $2.32 Average Price Target from Analysts

Cara Therapeutics, Inc. (NASDAQ:CARA) has received a consensus rating of “Hold” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. Five analysts have rated the stock with a hold rating. The average twelve-month price target among analysts that have covered the stock in the last year is $2.32.

Separately, StockNews.com began coverage on shares of Cara Therapeutics in a report on Wednesday. They issued a “sell” rating for the company.

Institutional Investors Weigh In On Cara Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. Disciplined Growth Investors Inc. MN raised its position in Cara Therapeutics by 6.6% during the second quarter. Disciplined Growth Investors Inc. MN now owns 1,935,718 shares of the biopharmaceutical company’s stock worth $499,000 after acquiring an additional 120,660 shares during the last quarter. FMR LLC increased its stake in shares of Cara Therapeutics by 18.5% during the 3rd quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 32,789 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of Cara Therapeutics during the 3rd quarter worth approximately $29,000. 44.66% of the stock is owned by institutional investors and hedge funds.

Cara Therapeutics Stock Performance

NASDAQ:CARA opened at $0.31 on Friday. Cara Therapeutics has a 1 year low of $0.24 and a 1 year high of $1.31. The stock has a fifty day moving average price of $0.29 and a two-hundred day moving average price of $0.40. The stock has a market capitalization of $17.06 million, a price-to-earnings ratio of -0.15 and a beta of 0.68.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The company had revenue of $0.99 million during the quarter, compared to analysts’ expectations of $1.26 million. Cara Therapeutics had a negative net margin of 1,010.20% and a negative return on equity of 241.31%. On average, analysts predict that Cara Therapeutics will post -1.24 EPS for the current year.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.